Introduction: Treatment decisions in localized prostate cancer are complicated by the available choices. A rapid-access cancer clinic (RAC) has been unique to Calgary, AB, since 2007. This RAC offers multidisciplinary prostate cancer education by a urologist, medical oncologist, and radiation oncologist. It is hypothesized that treatment utilization data from decisions taken at RAC may serve to benchmark the appropriateness of treatment decisions on a population level. 
Introduction
Prostate cancer is the most common non-dermatological cancer among men in developed countries and the third leading cause of cancer-related mortality.
1 Improved techniques and screening for prostate-specific antigen (PSA) have led to earlier detection and increased incidence of lowand intermediate-risk disease. 2 There are numerous treatment options available for low-and intermediate-risk prostate cancer, including active surveillance, radiation therapy (RT) (external beam or brachytherapy), hormone therapy, and surgery (radical prostatectomy). 3 Each of these treatment options has their own risks and benefits.
The majority of prostate cancer diagnoses are made through tests requested by the primary care provider, with subsequent treatment choice influenced by the type of specialist at first contact following referral. 4, 5 Treatment decisions are also known to be influenced by "subjective" factors, such as patient fear of surgery/radiation, concern over disease progression if untreated, perceived "best" treatment, and different priorities of treatment benefits and risks (e.g., sexual dysfunction). 6 Therefore, a considered approach to choosing the appropriate therapy for each patient requires balancing patient and disease characteristics (age, comorbidities, and Gleason score), life expectancy, and patient preference. 3 A rapid-access cancer clinic (RAC) has been operating in Calgary, Alberta since 2007 and offers multidisciplinary prostate cancer education to patients and their partners from a urologist, a medical oncologist, and a radiation oncologist in an evening session. The RAC conducts education sessions that aim to provide information on treatment options and allow for patients to engage with specialists so they are able to make an educated decision in discussion with their physician. It is hypothesized that treatment utilization data from decisions taken at RAC may serve to benchmark the appropriateness of treatment decisions on a population level.
Methods

Study population
This retrospective study examined the initial treatment received by Alberta patients with low-or intermediate-risk 7 This time period was selected for the cleanliness of data, as it was prior to expansion of treatment through a "radiation corridor" in Alberta. The two centralized and tertiary cancer centres would allow for a benchmark rate of RT utilization to be examined.
Source of data
This study was granted local research ethics board approval to access patient charts and health records. The Alberta Cancer Registry records and maintains data on all new cancer cases and cancer deaths occurring in the province; the data is known to be of very high quality and covers the entire Alberta population. 8 The Registry provides information on the date of diagnosis, collaborative stage, type and date of treatment, as well as personal information, such as date of birth, gender, provincial healthcare number, and postal code. Radiotherapy information from cancer centres in Alberta was electronically linked to the Alberta Cancer Registry. Patients' driving distances from residence to the cancer centres were calculated by entering each postal code at diagnosis and the postal code of the closest cancer centre, either the Cross Cancer Institute or the Tom Baker Cancer Centre, into Google Maps. All male adults aged over 18 diagnosed with localized prostate cancer between October 1, 2007 and September 30, 2009, residing in Alberta, Canada, and registered in the Alberta Cancer Registry were eligible for analysis.
Statistics
Descriptive statistics were calculated for the study variables and frequencies and percentages are reported. Clinical, treatment, and health service characteristics pertaining to patients attending RAC were compared to those managed elsewhere in Alberta. The categorical variables were compared between the two groups using Chi-square tests. The primary endpoint was utilization rates of initial treatment. A p value <0.05 was used for all statistical significance. All statistical analyses were performed using SAS (version 9.1).
Results
Patient characteristics
Between October 1, 2007 and September 30, 2009, 2838 men were diagnosed with low-or intermediate-risk localized prostate cancer and were evaluable for this analysis. Of these, 375 patients attended a RAC education session. There were 1903 men with low-risk localized prostate cancer treated in 2007. Of these, 22 patients attended a RAC education session. The highest proportion of patients in Alberta and the RAC subpopulation were between 60 and 69 years of age (Table 1 ). There was a statistically significant trend towards younger patients attending a RAC session. The time and distance from cancer treatment centre was significantly shorter for patients attending RAC compared to the general Alberta population. The income distribution was similar in the Alberta patients and the RAC subgroup. 2) use were either similar or lower. Among patients that received radiotherapy, there was a shift towards increased brachytherapy for patients that attended RAC (χ 2 p=0.002). In the low-risk localized prostate cancer population, surgery was still the most used first treatment, but the rate was lower and similar between the whole Alberta population (35.8%; 95% CI 33.7-38.0) and those that attended RAC (36.4%; 95% CI 19.7-57.0). Similar to the low and intermediate combined population, the patients that attended RAC were less likely to receive RT or hormone therapy than the general Alberta patient population. There was a substantial increase in active surveillance among patients that attended RAC (27.3%; 95% CI 13.2-48.2) compared with the general Alberta population with low-risk localized prostate cancer (15.6%; 95% CI 14.0-17.3).
Initial treatment
Discussion
There are numerous available and effective treatments for low-and intermediate-risk localized prostate cancer. 3 Many factors influence which treatment is used for each patient, including patient age, comorbidities, disease characteristics (e.g., Gleason score), and patient preference. [9] [10] [11] [12] [13] The initial point of contact with the health system is also important.
The proportion of patients that received surgery was higher in the combined low-and intermediate-risk subpopulation Vos et al of patients that attended RAC. This was influenced by the lower age distribution for patients that attended RAC, (as radical prostatectomy is generally not recommended for men >70 years of age 14 ) compared to standard "sequential-based practice" of presentation to a urologist followed by possible referral to a cancer centre. Among the patients that had RT as the first treatment, there was an increased probability of choosing brachytherapy for localized prostate cancer if the patient attended RAC. Active surveillance was also slightly higher in the subgroup of patients that attended RAC. It is rapid-access cancer clinic for prostate cancer understood that an inherent selection bias exists in a best practice clinic, in that the characteristics of the population under study influences the treatment options available to them. For RAC the population was younger and had closer proximity to a major cancer centre, but their socioeconomic status was no different from the rest of the prostate cancer population. We postulate that the information services provided at the RAC education sessions are consistent with best practice. Treatment decisions made by patients after participating in the session were likely mediated by alleviating cancer information concerns around treatment efficacy and side effects. A survey of 262 men with localized prostate cancer treated with either radical prostatectomy (n=81) or brachytherapy (n=167) revealed that, regardless of treatment, the source of greatest information was the urologist, followed by the internet. 15 When asked what factors influenced their treatment decision, the majority of patients made their treatment choice based on the belief that it gave the best chance of curing their cancer. For men that received radical prostatectomy, this was the main criterion of treatment choice (97.5% of patients). For men that received brachytherapy, the treatment effectiveness was most important for 49.1% of patients, while side effect profile was also listed as highly influential for treatment decisions (main criterion in 34.7% of patients). 15 The utilization rate of radiotherapy in Alberta is low, and even lower in patients that attended RAC. A Canadian study of RT use estimated that for patients with low-risk prostate cancer, 21.9% would have RT as first treatment and that this proportion would increase to 34.5% of patients with intermediate-risk prostate cancer. 9, 10 One of the reasons for the low RT use observed in Alberta may be because of the travel time associated with attending tertiary cancer centres. Studies have shown that likelihood of receiving RT decreases with increased travel time. 11 This effect will be addressed in the near future, with the expansion of RT capacity from two to five RT centres, allowing for 90% of patients to receive RT treatment within 100 km of home.
Interestingly, this study has shown that when providing access to a radiation oncologist, as provided in the RAC sessions, the observed RT rates are actually lower than expected. This is unlikely a result of different clinical outcomes, as surgery and RT for intermediate-risk prostate cancer have similar short-term survival benefits, 16 although it may be a function of the RAC population characteristics, including lower age. The higher proportion of patients that received surgery is not a clinically meaningful difference, but has a substantial impact on health system resource use. It may be that in the context of benchmarking appropriate RT or treatment rates in general, that the availability and accessibility of comparative information on treatment choices represents an unmet patient need. Not addressing such gaps in care may lead to population-level consequences involving health system resource allocation and patient outcomes.
